Form 4: Oncocyte Corp Director Andrew Arno Reports Stock Option Grant

Director Andrew Arno reports the acquisition of stock options in Oncocyte Corp.

Summary

• Andrew Arno, a director of Oncocyte Corp, filed a Form 4 with the SEC.
• The report details the grant of an option to purchase 20,000 shares of common stock at an exercise price of $2.76 on May 20, 2024.
• The options vest over a period of 4 years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The stock option grant is a positive incentive for the director, but it doesn't necessarily indicate a significant shift in the company's prospects.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules, such as the four-year vesting with a one-year cliff described in the document, are typical to ensure long-term commitment from the recipient.
• The size of the grant (20,000 shares) would need to be compared to similar grants at comparable companies to assess its relative significance.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders if the options are exercised in the future.

Key Dates